Raised: $38.56 million
Investors: Cycad Group, General Catalyst Partners, Hunt BioVentures, Longwood Founders Management, RA Capital Management, undisclosed investor
The scoop: At Sirtris Pharmaceuticals, Michelle Dipp played a key role in positioning the company for a $720 million sale to GlaxoSmithKline. Now as CEO of OvaScience, she has a big B round to advance work on stem cell technology for new fertility treatments. By taking mitochondria from a woman's ovarian stem cells and then inserting them - along with sperm - into eggs, OvaScience believes it can significantly improve the success rate for in vitro fertilization. The lead therapy is headed to the clinic later this year.